Developing antisense oligonucleotide and short‐interfering RNA therapeutics – a few considerations

E-ISSN： 2160-7648|4|5|323-325

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.4, Iss.5, 2015-09, pp. : 323-325

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Developing antisense oligonucleotide and short‐interfering RNA therapeutics – a few considerations

Clinical Pharmacology In Drug Development, Vol. 2160-763X, Iss. 5, 2015-09 ,pp. : 323-325

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antisense oligonucleotide therapeutics

By Bennett C.F.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 3, 1999-03 ,pp. : 255-255

Informa Healthcare

Access to resources Recommend Favorite

Antisense Anticancer Oligonucleotide Therapeutics

Current Cancer Drug Targets, Vol. 1, Iss. 3, 2001-01 ,pp. : 177-196

Bentham Science Publishers

Access to resources Recommend Favorite

Antisense and / or Immunostimulatory Oligonucleotide Therapeutics

Current Cancer Drug Targets, Vol. 1, Iss. 3, 2001-11 ,pp. : 197-209

Bentham Science Publishers

Access to resources Recommend Favorite

Recent progress in oligonucleotide therapeutics: antisense to aptamers

By Leaman Douglas W

Expert Opinion on Drug Discovery, Vol. 3, Iss. 9, 2008-09 ,pp. : 997-1009

Informa Healthcare

Access to resources Recommend Favorite